Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628141 | 0.91 | MEN1 (0.47) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL4630887 | 0.85 | GSK3A (0.53) | GSK3ACDK9CDK5TAOK1CLK4 | |
| Hydrochloric Acid SCHEMBL7857018 | 0.83 | GSK3A (0.51) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL5787755 | 0.82 | KDR (0.47) | KDRALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL31355480 | 0.78 | KMT2A (0.57) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL31355479 | 0.78 | KMT2A (0.57) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL3948701 | 0.78 | KMT2A (0.57) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL30206142 | 0.78 | KMT2A (0.57) | KDRALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL618299 | 0.78 | KMT2A (0.57) | KDRALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL22971333 | 0.75 | KDR (0.44) | KDRALDH1A1HPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210980-B1 | PROCESS FOR MANUFACTURING 5-[[4-[[MORPHOLIN-2-YL]METHYLAMINO]-5-(TRIFLUOROMETHYL)- 2-PYRIDYL]AMINO]PYRAZINE-2-CARBONITRILE | CANCER RESEARCH TECH LTD (GB) | 2024-04-03 | — | — | EP | disclosed |
| US-11787792-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20210276990-A1 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10870624-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | US | disclosed |
| US-10407435-B2 | Diheteroaryl histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| US-10407435-B2 | Diheteroaryl histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| CN-106279142-B | 5- [[4- [[morpholine -2-yl] methylamino]-5- (trifluoromethyl)-2- pyridyl group] amino] pyrazine-2- nitrile and its treatment use | 癌症研究技术有限公司 | 2019-05-03 | — | — | CN | disclosed |
| US-10259806-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| EP-2197874-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| EP-2197874-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009029617-A1 | DIARYLAMINE-SUBSTITUTED QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276990-A1 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | CHEK1, CHEK2, BUB1B | GSK3A 163/4885CDK9 79/4885CDK5 65/4885 |
| US-10407435-B2 | Diheteroaryl histone deacetylase inhibitors and their use in therapy | HDAC1, HDAC11, HDAC7 | GSK3A 306/4885CDK9 1077/4885CDK5 1977/4885 |
| US-11787792-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof | CHEK1, CHEK2, BUB1B | GSK3A 163/4885CDK9 79/4885CDK5 65/4885 |
| US-10259806-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | CHEK1, CHEK2, CDK1 | GSK3A 155/4885CDK9 78/4885CDK5 58/4885 |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC3 | GSK3A 3557/4885CDK9 1543/4885CDK5 326/4885 |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, BUB1B | GSK3A 243/4885CDK9 130/4885CDK5 45/4885 |
| US-10870624-B2 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC2 | GSK3A 515/4885CDK9 716/4885CDK5 923/4885 |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | MCL1, HDAC1, MYC | GSK3A 130/4885CDK9 620/4885CDK5 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.